论文部分内容阅读
目的探讨重组人P53腺病毒注射液联合介入治疗肝癌的临床应用价值。方法选择18例患者使用重组人P53腺病毒注射液联合介入治疗,并与单纯使用介入治疗者比较两组临床疗效以及治疗后1个月患者Karuafsk变化情况。结果观察组有效率显著高于对照组(P<0.05),观察组患者治疗后1个月Karuafsk较治疗前显著提高(P<0.05),治疗后1个月观察组Karuafsk较对照组显著提高(P<0.05)。结论对于原发性肝癌,在介入注射化疗药物的基础上,使用重组人P53腺病毒注射液能更好地改善患者生存质量,提高临床效果,可以考虑临床使用。
Objective To investigate the clinical value of recombinant human P53 adenovirus injection combined with interventional treatment of liver cancer. Methods 18 patients were treated with recombinant human P53 adenovirus injection in combination with interventional therapy, and the clinical efficacy and the Karuafsk changes at 1 month after treatment were compared between the two groups. Results The effective rate of observation group was significantly higher than that of control group (P <0.05). Karuafsk significantly increased (P <0.05) at 1 month after treatment in observation group and Karuafsk in observation group at 1 month after treatment P <0.05). Conclusion For primary hepatocellular carcinoma, on the basis of interventional chemotherapeutic drugs, the use of recombinant human P53 adenovirus injection can better improve the quality of life of patients and improve the clinical effect, we can consider the clinical use.